Menu

Top Stories

Published on Thursday, May 28, 2015

The Lancet publishes RAPID trial results showing effectiveness of Alpha-1 augmentation therapy

The Lancet publishes RAPID trial results showing effectiveness of Alpha-1 augmentation therapy

The Alpha-1 Foundation on Thursday congratulated the investigators and sponsor of the RAPID Trial, demonstrating the effectiveness of augmentation therapy in slowing emphysema due to Alpha-1 Antitrypsin Deficiency, on the publication of the trial in The Lancet, one of the world’s oldest and most prestigious medical journals.

The Lancet article was posted online this week.

When the results were first announced at the international conference of the American Thoracic Society (ATS) in 2013, lead author Kenneth Chapman, MD, director of the Asthma and Airway Centre of the University Health Network in Toronto, Canada, called the trial “the most rigorous evidence to date that augmentation therapy slows the progression of emphysema in patients with Alpha-1 Antitrypsin Deficiency. The effect of A1-PI seen in this trial was both clinically and statistically significant, finally confirming its benefit in preventing the loss of lung tissue in patients with this potentially debilitating disease.”

The Alpha-1 Foundation hailed the trial results and The Lancet publication. "We congratulate CSL on this landmark clinical trial, which provides the strongest evidence yet that augmentation therapy preserves the lung tissue of individuals with Alpha-1-related lung disease," said John Walsh, Foundation president and CEO. "We hope these results will support Alpha-1 communities around the world in their efforts to win access to therapy.”

Walsh said, “The Foundation has communicated its support for acceptance of the RAPID data as proof of efficacy of augmentation therapy to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (the European equivalent of the FDA), and has continued a dialogue with both agencies to urge acceptance of these findings.”

CSL Behring sponsored the trial, which randomly assigned 180 Alpha-1 patients to receive either the augmentation product Zemaira or a placebo for a two-year period, followed by a two year of open-label extension study in which all subjects were offered augmentation therapy. “We applaud CSL for its commitment of time and effort to conduct this multinational, multi-year study, and we’re delighted that The Lancet has published the RAPID Trial results,” said Walsh. 

The Lancet article says that an interim analysis of data from the two-year extension trial suggest that early treatment with augmentation therapy shows persistent efficacy in patients with Alpha-1 and emphysema. In addition, when patients who had been receiving a placebo in the original two-year trial switched to treatment with augmentation therapy, their lung density decline (which was more rapid than the treated group in the main study) slowed to the same rate as the treatment group. “These findings should encourage early introduction of augmentation therapy [in patients with emphysema due to Alpha-1] and should stimulate further research into optimum dosing,” says the Lancet article.

Robert Sandhaus, MD, PhD, clinical director of the Alpha-1 Foundation and medical director of AlphaNet, was a co-author of the Lancet article.

The RAPID Trial is the first well-powered randomized, placebo-controlled trial to use CT scan lung density as the primary outcome measure. CT scans are currently considered the most sensitive measure of emphysema detection. The trial was conducted at 28 sites in the United States, Europe, Canada, Australia and Russia.

The multi-center, multi-national trial randomized patients with homozygous Alpha-1 (ZZ) to receive either alpha-1 antitrypsin augmentation therapy intravenously at 60 mg/kg weekly or a placebo over two years. CT scan lung density was measured at baseline, three months, one and two years. Secondary endpoints included spirometry, changes in exercise capacity and the rate of pulmonary exacerbations over two years.

The annual rate of lung density loss was significantly less in augmentation-treated patients (-1.45 +/- 0.24 units vs. -2.19 +/-0.25 units; p = 0.017, one-sided). Secondary outcome variables and adverse events were not significantly different between groups, according to the article. There was one death in the augmentation therapy group and three in the placebo group.

Attached is the full article published in The Lancet, with an accompanying editorial by Ronald Crystal, MD, Department of Genetic Medicine, Weill Cornell Medical College.

Photo at top: Ken Chapman, MD. Below: John Walsh, left, and Robert Sandhaus, MD.


Print

Emergency preparation and lung disease

Wednesday, September 12, 2018
Everyone, especially patients that require the use of oxygen or other special medical equipment, should never wait long before putting an emergency plan into practice, for emergencies, catastrophes or natural or man-made disasters. And putting...
Divider

Augmentation therapy patient-pioneer, Gerry Treichel, passes away

Wednesday, September 12, 2018
It is with a heavy heart that the Alpha-1 Foundation announces the passing of Gerald (Gerry) Treichel, beloved member of the Alpha-1 community for many years and one of the pioneer patients for augmentation therapy, in the evening of Sunday,...
Divider

A good age: Denied a lung transplant, she keeps on trekking

Tuesday, September 11, 2018
In her determination, Alyce Yout has a compelling courage and buoyancy. After living with lung disease for 26 years, the former pediatric nurse had high hopes for a lung transplant last fall. “We began the journey to a transplant after...
Divider

Sharp drop in portable oxygen access blamed on provider pay changes

Monday, September 10, 2018
A coalition of pulmonary health groups called on the Centers for Medicare & Medicaid Services (CMS) to change its supplemental oxygen reimbursement policy to remove liquid oxygen from competitive bidding requirements. The American Lung...
Divider

New advances in gene therapies for rare diseases

Friday, August 31, 2018
The U.S. Food and Drug Administration (FDA) recently approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This...
Divider

Alpha-1 Foundation leadership transition

Wednesday, August 22, 2018
The Alpha-1 Foundation Board of Directors is pleased to announce that Miriam O’Day has been named as interim CEO of the Alpha-1 Foundation. Ms. O’Day has served the Foundation with distinction for nearly twenty years. The Board is...
Divider

Alpha-1 Foundation earns 8th consecutive 4-star rating from Charity Navigator

Wednesday, August 22, 2018
The Alpha-1 Foundation has earned its eighth consecutive 4-star rating from Charity Navigator, an accomplishment that only select charities achieve in the U.S. The Foundation earned its top score based on Charity Navigator’s evaluation of...
Divider

Orphan Drug Designation granted to Bronchiolitis Obliterans treatment

Friday, August 17, 2018
Onspira Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to its investigational product, OSP-101, for the treatment of Bronchiolitis Obliterans (BO). BO is a progressive inflammatory condition...
Divider

Family of liver donor meets transplant recipient

Friday, August 10, 2018
On June 19, Cletus Schnieders was eating dinner with his wife Carrie and their three children (sons Trenton, 9, and Cletie, 4, and daughter Samantha, 2) in their Cincinnati home when he started to choke. Photo: Facebook/Carrie...
Divider

Living donor saved her own son’s life

Tuesday, July 31, 2018
Dara Kass is an emergency physician in New York, but she did not need to be a doctor to know that something was going on with the third child, Sammy. At birth, the baby was smaller than his two siblings. He barely grew and was lethargic; his skin...
Divider

The Assistance Fund opens new program for Alphas

Monday, July 30, 2018
The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, announced the launch of a new program for individuals with Alpha-1 Antitrypsin Deficiency...
Divider

Alpha-1 Foundation board has new Chair

Friday, July 27, 2018
The Alpha-1 Foundation has the honor to announce that Jeanine D’Armiento, MD, PhD, has been named as the newest Chair of its board of directors. D’Armiento has served on the Foundation’s board since 2011, and before that, she had...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive